This article is more than 5 years old. Information may no longer be current.

Regeneron reports revenue increase for 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Regeneron reported its fourth quarter 2018 GAAP net income at $820 million, a 371% increase from the fourth quarter 2017 GAAP net income.

For the full year, Regeneron reported $2.4 billion in GAAP net income, a 104% increase over the 2017 full year.

Net sales of Eylea (aflibercept) injection in the U.S. increased 11% to $1.08 billion in the fourth quarter of 2018 vs. $975 million, an increase of 11%, in the same quarter of 2017.

For the full year, Eylea net product sales were $4.08 billion compared with $3.7 billion for the full year 2017. Fourth quarter 2018 sales of Eylea outside of the U.S. increased by 14% to $724 million.

Regeneron reported $1.93 billion in fourth quarter 2018 revenues and $6.7 billion for the full year, up 22% and 14% over the previous year’s same reporting periods.